- GlobeNewswire•20 days ago
Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Failure
NEW YORK and MELBOURNE, Australia, April 10, 2017-- Mesoblast Limited today announced that the Phase 3 trial of its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in patients with moderate ...
- GlobeNewswire•24 days ago
Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
NEW YORK and MELBOURNE, Australia, April 06, 2017-- Mesoblast Limited today announced that it has received A $3.7 million from the Australian Government for Research & Development activities conducted ...
- GlobeNewswire•26 days ago
FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease
BOSTON, NEW YORK, and MELBOURNE, Australia, April 03, 2017-- Boston Children’ s Hospital, the pediatric teaching hospital of Harvard University, and Mesoblast Limited today announced that the United States ...
MSB.AX : Summary for MESOBLAST FPO - Yahoo Finance
Mesoblast Limited (MSB.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||3.14 - 3.38|
|52 Week Range||1.01 - 3.44|
|PE Ratio (TTM)||-143.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|